Zalviso

RSS

sufentanil

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Zalviso. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zalviso.

For practical information about using Zalviso, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 12/07/2017

Authorisation details

Product details
Name
Zalviso
Agency product number
EMEA/H/C/002784
Active substance
sufentanil
International non-proprietary name (INN) or common name
sufentanil
Therapeutic area (MeSH)
Pain, Postoperative
Anatomical therapeutic chemical (ATC) code
N01AH03
Publication details
Marketing-authorisation holder
Grünenthal GmbH
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
18/09/2015
Contact address
Zieglerstr. 6
D-52078Aachen
Germany

Product information

22/05/2017 Zalviso - EMEA/H/C/002784 - N/0008

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ANESTHETICS

Therapeutic indication

Zalviso is indicated for the management of acute moderate to severe post-operative pain in adult patients.

Assessment history

How useful was this page?

Add your rating